Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Cancer. 2019 May 23;125(18):3147–3154. doi: 10.1002/cncr.32185

Figure 3. Cumulative incidence plots showing the probability of progression to muscle-invasive bladder cancer (MIBC) or bladder cancer death (panel A) and of bladder cancer death (panel B).

Figure 3.

Data are from propensity score adjusted Fine and Gray competing risk models with death from other causes modeled as a competing risk. Median length of follow-up was 4.8 years.

Blue line: recommended surveillance; red line: frequent surveillance.

Note: In panel A, blue and red lines almost completely overlap.